Bicycle Therapeutics, a next generation biotherapeutics UK-based company developing first-in-class bicyclic peptides, announced that it had secured an equity financing of €25 million for the clinical development of therapeutic bicycle drug candidates in oncology.
Bicycle has used its proprietary bicyclic peptide technology that enables to discover a new class of drug candidates, which have similar selectivity and potency to antibodies but are 100-fold smaller and are manufactured using simple, economic chemical synthesis. This financing will support the clinical development of bicycle-drug conjugates (BDCs) that are highly selective to tumour-specific targets, with sub-nanomolar affinities. Preclinical models show that these BDCs extravasate and penetrate tissues much more rapidly and efficiently than antibodies, effecting rapid cell killing through the tumour mass and fast clearance. This results in effective tumour lysis with minimal systemic exposure.
You can have a look on this video. The models are the molecular dynamics of the same amino acid sequence as a linear peptide (left), as a monocycle (centre) and as a bicycle (right). The higher constraint of the bicycle results in the three side chains being more frequently in the correct orientation to bind with the target.